Over two decades helping clients navigate the difficult path of regulatory compliance.

mms holdings building

In 2006, MMS was created by Dr. Uma Sharma, with a vision to turn a one-person consultancy into a global, data-focused CRO that caters to the unique and often changing needs of sponsors. Years later, with an industry-leading customer satisfaction rating, MMS stays true to its dependable and customer-driven nature. A science-first approach and strong processes have smoothed the waters for MMS clients resulting in positive organic growth year over year, with more than 950 colleagues worldwide.

MMS is a place where years of proven success have guided sponsors through their data services and regulatory submissions goals. When MMS takes on a project, colleagues become ingrained in that sponsor – taking on a greater level of care and guiding them towards a positive outcome.

Sponsors that demand high quality come to MMS for strong industry expertise, a scientific approach to drug development, and top talent. Sponsors stay with MMS for its flexibility, agility, and a “do what it takes” attitude that is unrivaled in the industry.

With a global footprint across four continents, MMS was proud to be named Best CRO – Specialist Provider in the Scrip Awards and Best Data-Focused CRO in the GHP Global Excellence Awards. In addition, MMS is certified as a Top Workplace in the United States and Michigan for two consecutive years as well as a Certified Great Place to Work in India.

Recently, the TOGETHER Trial, which uses an Electronic Data Capture (EDC) system designed, built, and maintained by MMS, won the Society for Clinical Trial’s annual Trial of the Year Award.

To deliver high-quality service and technology solutions – rooted in strong science and decades of regulatory experience – that will assist our clients in developing and marketing life-changing therapies to positively improve lives worldwide.

Our Values

Strive for Good Science and Strong Processes

MMS is committed to making sound decisions based on strong scientific principles, internal expertise, and applicable regulation. As an organization, MMS emphasizes and values strong internal processes through defining, following, and improving upon the steps that lead to high-quality deliverables.

Value Talent – Find, Attract, Enhance and Retain

MMS recognizes that a talented staff is what drives our business forward. Identifying and attracting top talent and continual training to strengthen core skills are essential to core mission. At MMS, enthusiasm, collaboration, and teamwork is fostered, knowing that a global and diverse talent pool makes the company stronger.

Wow the Customer

MMS believes in delivering value beyond the competition. Each sponsor and researcher that MMS partners with is important and their goals relevant. MMS will strive to exceed their expectations by maintaining a customer focus throughout the project lifecycle, ensuring the customer experience is positive, building trust and forging long-term relationships.

Bring a Sense of Urgency and Leadership (SOUL)

MMS promotes the importance of SOUL through a healthy work environment and as a requirement for providing added value to clients. The SOUL of MMS comes to life as project work is completed on time and as risks and solutions are identified proactively. At MMS, each colleague takes responsibility for the success of every project.

Suggested For You

webinar

September 26th, 2024

Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance

regulatory intelligence

August 27th, 2024

Recent Guidance on Diversity Action Planning

regulatory intelligence

August 26th, 2024

Oncology Programs at the FDA

regulatory intelligence

August 26th, 2024

Three Key Take Reflections on the Recent Donanemab Approval

webinar

September 12th, 2024

No Stone Unturned: Optimizing the Use of Expedited Pathways and Oncology Center of Excellence Programs to Optimize Drug Development in Oncology

regulatory intelligence

August 9th, 2024

FDA Updates 2024 Language Access Plan

regulatory intelligence

August 3rd, 2024

EMA Launches New Pilot Program for Orphan Medical Devices

perspectives

July 30th, 2024

The Critical Role of Quality Control (QC) – Medical Writing and Beyond

regulatory intelligence

July 26th, 2024

Key Decision Points for Recent Oncology Approvals

regulatory intelligence

July 24th, 2024

Comments Open for Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products

perspectives

July 23rd, 2024

PSI 2024 Ignited Conversations on External Data Sources, Requirements for Estimands, and Bayesian Methodology for Statisticians in Pharma

news

July 17th, 2024

Industry Veteran Ben Dudley Joins MMS as Chief Commercial Officer (CCO) to Drive Continued Growth for the Data-focused Clinical Research Organization